HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A correction has been published Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Straathof, K. C. Articles by Bollard, C. M. Search for Related Content PubMed PubMed Citation Articles by Straathof, K. C. Articles by Bollard, C. M. Pubmed/NCBI databases Medline Plus Health Information Hodgkin Disease

Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma¹

Karin C. Straathof^*, Ann M. Leen^*, Elizabeth L. Buza^*, Graham Taylor^||, M. Helen Huls^*, Helen E. Heslop^*,,, Cliona M. Rooney^*,,,¶ and Catherine M. Bollard^2,*,,,¶

^* Center for Cell and Gene Therapy, Department of Pediatrics, Department of Medicine, Department of Molecular Virology and Microbiology, and ^¶ Department of Immunology, Baylor College of Medicine, Methodist Hospital and Texas Children’s Hospital, Houston, TX 77030; and ^|| Cancer Research United Kingdom Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom

Viral proteins expressed by EBV-associated tumors provide target Ags for immunotherapy. Adoptive T cell therapy has proven effective for posttransplant EBV-associated lymphoma in which all EBV latent Ags are expressed (type III latency). Application of immunotherapeutic strategies to tumors such as nasopharyngeal carcinoma and Hodgkin’s lymphoma that have a restricted pattern of EBV Ag expression (type II latency) is under investigation. Potential EBV Ag targets for T cell therapy expressed by these tumors include latent membrane proteins (LMP) 1 and 2. A broad panel of epitopes must be identified from these target Ags to optimize vaccination strategies and facilitate monitoring of tumor-specific T cell populations after immunotherapeutic interventions. To date, LMP2 epitopes have been identified for only a limited number of HLA alleles. Using a peptide library spanning the entire LMP2 sequence, 25 CTL lines from patients with EBV-positive malignancies expressing type II latency were screened for the presence of LMP2-specific T cell populations. In 21 of 25 lines, T cell responses against one to five LMP2 epitopes were identified. These included responses to previously described epitopes as well as to newly identified HLA-A*0206-, A*0204/17-, A29-, A68-, B*1402-, B27-, B*3501-, B53-, and HLA-DR-restricted epitopes. Seven of the nine newly identified epitopes were antigenically conserved among virus isolates from nasopharyngeal carcinoma tumors. These new LMP2 epitopes broaden the diversity of HLA alleles with available epitopes, and, in particular, those epitopes conserved between EBV strains provide valuable tools for immunotherapy and immune monitoring.

This article has been cited by other articles:

				A. M. Leen, A. Christin, G. D. Myers, H. Liu, C. R. Cruz, P. J. Hanley, A. A. Kennedy-Nasser, K. S. Leung, A. P. Gee, R. A. Krance, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation Blood, November 5, 2009; 114(19): 4283 - 4292. [Abstract] [Full Text] [PDF]

				C. U. Louis, K. Straathof, C. M. Bollard, C. Gerken, M. H. Huls, M. V. Gresik, M.-F. Wu, H. L. Weiss, A. P. Gee, M. K. Brenner, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients Blood, March 12, 2009; 113(11): 2442 - 2450. [Abstract] [Full Text] [PDF]

				M. H. Fogg, L. J. Wirth, M. Posner, and F. Wang Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma PNAS, March 3, 2009; 106(9): 3318 - 3323. [Abstract] [Full Text] [PDF]

				T. A. Haigh, X. Lin, H. Jia, E. P. Hui, A. T. C. Chan, A. B. Rickinson, and G. S. Taylor EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+ Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines J. Immunol., February 1, 2008; 180(3): 1643 - 1654. [Abstract] [Full Text] [PDF]

				A. M. Leen, A. Christin, M. Khalil, H. Weiss, A. P. Gee, M. K. Brenner, H. E. Heslop, C. M. Rooney, and C. M. Bollard Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy J. Virol., January 1, 2008; 82(1): 546 - 554. [Abstract] [Full Text] [PDF]

				M. Niens, R. F. Jarrett, B. Hepkema, I. M. Nolte, A. Diepstra, M. Platteel, N. Kouprie, C. P. Delury, A. Gallagher, L. Visser, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma Blood, November 1, 2007; 110(9): 3310 - 3315. [Abstract] [Full Text] [PDF]

				C. M. Bollard, S. Gottschalk, A. M. Leen, H. Weiss, K. C. Straathof, G. Carrum, M. Khalil, M.-f. Wu, M. H. Huls, C.-C. Chang, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer Blood, October 15, 2007; 110(8): 2838 - 2845. [Abstract] [Full Text] [PDF]